0.8982Delayed Data As of 3:24pm ET | -0.0117 / -1.29%Today’s Change | 0.72 Today|||52-Week Range 3.20 | -11.94% Year-to-Date |
SECTOR Health Services | INDUSTRY Services to the Health Industry | MARKET CAP $29.0M |
Company Description
Interpace Diagnostics Group, Inc. is an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
Employees

Shareholders
Mutual fund holders | 3.01% |
Other institutional | 10.09% |
Individual stakeholders | 0.60% |
Top Executives
Jack E. Stover | President, Chief Executive Officer & Director |
Glenn Gershon | Senior Vice President-Operations |
James Early | Chief Financial Officer. Secretary & Treasurer |
Sydney D. Finkelstein | Chief Scientific Officer |
Sara A. Jackson | Vice President-Clinical Development |